The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes
Abstract
Islet amyloid deposition is a pathogenic feature of type 2 diabetes, and these deposits contain the unique amyloidogenic peptide islet amyloid polypeptide. Autopsy studies in humans have demonstrated that islet amyloid is associated with loss of beta-cell mass, but a direct role for amyloid in the pathogenesis of type 2 diabetes cannot be inferred from such studies. Animal studies in both spontaneous and transgenic models of islet amyloid formation have shown that amyloid forms in islets before fasting hyperglycemia and therefore does not arise merely as a result of the diabetic state. Furthermore, the extent of amyloid deposition is associated with both loss of beta-cell mass and impairment in insulin secretion and glucose metabolism, suggesting a causative role for islet amyloid in the islet lesion of type 2 diabetes. These animal studies have also shown that beta-cell dysfunction seems to be an important prerequisite for islet amyloid formation, with increased secretory demand from obesity and/or insulin resistance acting to further increase islet amyloid deposition. Recent in vitro studies suggest that the cytotoxic species responsible for islet amyloid-induced beta-cell death are formed during the very early stages of islet amyloid formation, when islet amyloid polypeptide aggregation commences. Interventions to prevent islet amyloid formation are emerging, with peptide and small molecule inhibitors being developed. These agents could thus lead to a preservation of beta-cell mass and amelioration of the islet lesion in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
Common core structure of amyloid fibrils by synchrotron X-ray diffraction 1 1Edited by F. E. Cohen
Sunde, M., Serpell, L. C., Bartlam, M., Fraser, P. E., Pepys, M. B., & Blake, C. C. F. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1348 · Cited by 1,707
Cited by
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Type 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus
Westermark, P., Andersson, A., & Westermark, G. T. (2011) · Physiological Reviews · doi:10.1152/physrev.00042.2009 · Cited by 1,044
“This pathological characteristic is most probably of great importance for the development of the -cell failure in this disease (146, 171), but the molecule also has regulatory properties in normal physiology.”
BackgroundSelf-citationProtein aggregation diseases: pathogenicity and therapeutic perspectives
Aguzzi, A., & O'Connor, T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3050 · Cited by 762
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Mechanisms controlling pancreatic islet cell function in insulin secretion
Campbell, J. E., & Newgard, C. B. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00317-7 · Cited by 629
Defining and Characterizing the Progression of Type 2 Diabetes
Fonseca, V. A. (2009) · Diabetes Care · doi:10.2337/dc09-s301 · Cited by 573
Management of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Prions: Protein Aggregation and Infectious Diseases
Aguzzi, A., & Calella, A. M. (2009) · Physiological Reviews · doi:10.1152/physrev.00006.2009 · Cited by 504
Physicochemical Properties of Cells and Their Effects on Intrinsically Disordered Proteins (IDPs)
Theillet, F.-X., Binolfi, A., Frembgen-Kesner, T., Hingorani, K., Sarkar, M., Kyne, C., Li, C., Crowley, P. B., Gierasch, L., Pielak, G. J., et al. (2014) · Chemical Reviews · doi:10.1021/cr400695p · Cited by 503
Taylor, R. (2013) · Diabetes Care · doi:10.2337/dc12-1805 · Cited by 485
“Insulin resistance may be caused by an insulin signaling defect (5), glucose transporter defect (6), or lipotoxicity (7), and b-cell dysfunction is postulated to be caused by amyloid deposition in the islets (8), oxidative stress (9), excess fatty acid (10), or lack of incretin effect (11).”
The Transcellular Spread of Cytosolic Amyloids, Prions, and Prionoids
Aguzzi, A., & Rajendran, L. (2009) · Neuron · doi:10.1016/j.neuron.2009.12.016 · Cited by 473
Mechanisms of β-Cell Death in Type 2 Diabetes
Donath, M. Y., Ehses, J. A., Maedler, K., Schumann, D. M., Ellingsgaard, H., Eppler, E., & Reinecke, M. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s108 · Cited by 444
Prediction of Aggregation-Prone Regions in Structured Proteins
Tartaglia, G. G., Pawar, A. P., Campioni, S., Dobson, C. M., Chiti, F., & Vendruscolo, M. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.05.013 · Cited by 437
Targeting innate immune mediators in type 1 and type 2 diabetes
Donath, M. Y., Dinarello, C. A., & Mandrup-Poulsen, T. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0213-9 · Cited by 416
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
Maggio, C. A., & Pi-Sunyer, F. X. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00071-9 · Cited by 351
Type 2 diabetes as a protein misfolding disease
Mukherjee, A., Morales-Scheihing, D., Butler, P. C., & Soto, C. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.005 · Cited by 342
Implications of peptide assemblies in amyloid diseases
Ke, P. C., Sani, M.-A., Ding, F., Kakinen, A., Javed, I., Separovic, F., Davis, T. P., & Mezzenga, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00372b · Cited by 338
Islet Inflammation in Type 2 Diabetes
Donath, M. Y., Schumann, D. M., Faulenbach, M., Ellingsgaard, H., Perren, A., & Ehses, J. A. (2008) · Diabetes Care · doi:10.2337/dc08-s243 · Cited by 334
Islet Inflammation Impairs the Pancreatic β-Cell in Type 2 Diabetes
Donath, M. Y., Böni-Schnetzler, M., Ellingsgaard, H., & Ehses, J. A. (2009) · Physiology · doi:10.1152/physiol.00032.2009 · Cited by 330
Epigenetic Regulation of the DLK1-MEG3 MicroRNA Cluster in Human Type 2 Diabetic Islets
Kameswaran, V., Bramswig, N. C., McKenna, L. B., Penn, M., Schug, J., Hand, N. J., Chen, Y., Choi, I., Vourekas, A., Won, K.-J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.016 · Cited by 318
Conserved and Cooperative Assembly of Membrane-Bound α-Helical States of Islet Amyloid Polypeptide
Knight, J. D., Hebda, J. A., & Miranker, A. D. (2006) · Biochemistry · doi:10.1021/bi060579z · Cited by 309
Heparan Sulfate: Biosynthesis, Structure, and Function
(2016) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.02.009 · Cited by 298
Islet β cell mass in diabetes and how it relates to function, birth, and death
Weir, G. C., & Bonner‐Weir, S. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12031 · Cited by 296
Teixeira-Lemos, E., Nunes, S., Teixeira, F., & Reis, F. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-12 · Cited by 284
Meng, F., Abedini, A., Plesner, A., Verchere, C. B., & Raleigh, D. P. (2010) · Biochemistry · doi:10.1021/bi100939a · Cited by 282
Chapter 3 Interactions Between Heparan Sulfate and Proteins—Design and Functional Implications
(2009) · International Review of Cell and Molecular Biology · doi:10.1016/s1937-6448(09)76003-4 · Cited by 274
Islet amyloid polypeptide: structure, function, and pathophysiology
Akter, R., Cao, P., Noor, H., Ridgway, Z., Tu, L.-H., Wang, H., Wong, A. G., Zhang, X., Abedini, A., Schmidt, A. M., et al. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2798269 · Cited by 273
“The concentration of IAPP in the granule is noticeably lower than that of insulin, about 1%-2% of the insulin level, but it is still much higher than that required to promote rapid amyloid formation in vitro [66, 67].”
Backgroundβ-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Saisho, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.109 · Cited by 263
The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality
Kahn, S. E., Zraika, S., Utzschneider, K. M., & Hull, R. L. (2009) · Diabetologia · doi:10.1007/s00125-009-1321-z · Cited by 260
Self-citationDiabetes and beta cell function: from mechanisms to evaluation and clinical implications
Cernea, S., & Dobreanu, M. (2013) · Biochemia Medica · doi:10.11613/bm.2013.033 · Cited by 203
Apoptosis in pancreatic β-islet cells in Type 2 diabetes
Tomita, T. (2016) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2016.919 · Cited by 197
The dynamic plasticity of insulin production in β-cells
Boland, B. B., Rhodes, C. J., & Grimsby, J. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.010 · Cited by 194
“IAPP aggregates form prior to the onset of frank T2DM during fasting hyperglycemia, implicating the onset of b-cell secretory dysfunction prior to IAPP aggregate deposition [215].”
BackgroundHuman IAPP–induced pancreatic β cell toxicity and its regulation by autophagy
Shigihara, N., Fukunaka, A., Hara, A., Komiya, K., Honda, A., Uchida, T., Abe, H., Toyofuku, Y., Tamaki, M., Ogihara, T., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69866 · Cited by 177
Pancreatic islet inflammation in type 2 diabetes: From α and β cell compensation to dysfunction
Ehses, J. A., Ellingsgaard, H., Böni-Schnetzler, M., & Donath, M. Y. (2009) · Archives of Physiology and Biochemistry · doi:10.1080/13813450903025879 · Cited by 97
Diffusing protein binders to intrinsically disordered proteins
Liu, C., Wu, K., Choi, H., Han, H. L., Zhang, X., Watson, J. L., Ahn, G., Zhang, J. Z., Shijo, S., Good, L. L., et al. (2025) · Nature · doi:10.1038/s41586-025-09248-9 · Cited by 79
Muff, R., Born, W., Lutz, T. A., & Fischer, J. A. (2004) · Peptides · doi:10.1016/j.peptides.2004.08.007 · Cited by 62
Matsuda, Y. (2019) · Pathology International · doi:10.1111/pin.12837 · Cited by 61
Diffusing protein binders to intrinsically disordered proteins
Liu, C., Wu, K., Choi, H., Han, H., Zhang, X., Watson, J. L., Shijo, S., Bera, A. K., Kang, A., Brackenbrough, E., et al. (2024) · doi:10.1101/2024.07.16.603789 · Cited by 24
Comprehensive Nanorobotic Control of Human Morbidity and Aging
Freitas, R. A. (2010) · The Future of Aging · doi:10.1007/978-90-481-3999-6_23 · Cited by 16
Metadata
- Authors
- Hull, R. L., Westermark, G. T., Westermark, P., & Kahn, S. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-08
- Volume
- 89
- Issue
- 8
- Pages
- 3629-3643
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2136989779
- Cited by
- 583
- References
- 219
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.